RS63572B1 - Urat1 inhibitor i njegova upotreba - Google Patents
Urat1 inhibitor i njegova upotrebaInfo
- Publication number
- RS63572B1 RS63572B1 RS20220866A RSP20220866A RS63572B1 RS 63572 B1 RS63572 B1 RS 63572B1 RS 20220866 A RS20220866 A RS 20220866A RS P20220866 A RSP20220866 A RS P20220866A RS 63572 B1 RS63572 B1 RS 63572B1
- Authority
- RS
- Serbia
- Prior art keywords
- urat1 inhibitor
- urat1
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611008935 | 2016-11-16 | ||
CN201711115037.9A CN108084186B (zh) | 2016-11-16 | 2017-11-13 | Urat1抑制剂及其应用 |
PCT/CN2017/111013 WO2018090921A1 (zh) | 2016-11-16 | 2017-11-15 | Urat1抑制剂及其应用 |
EP17872538.8A EP3543240B1 (en) | 2016-11-16 | 2017-11-15 | Urat1 inhibitor and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
RS63572B1 true RS63572B1 (sr) | 2022-10-31 |
Family
ID=62172162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20220866A RS63572B1 (sr) | 2016-11-16 | 2017-11-15 | Urat1 inhibitor i njegova upotreba |
Country Status (18)
Country | Link |
---|---|
US (2) | US10875865B2 (sr) |
EP (1) | EP3543240B1 (sr) |
JP (1) | JP6925054B2 (sr) |
KR (1) | KR102263441B1 (sr) |
CN (1) | CN108084186B (sr) |
AU (1) | AU2017360465B2 (sr) |
CA (1) | CA3043942C (sr) |
DK (1) | DK3543240T3 (sr) |
ES (1) | ES2923177T3 (sr) |
HR (1) | HRP20221151T1 (sr) |
HU (1) | HUE059778T2 (sr) |
IL (1) | IL266587B2 (sr) |
MX (1) | MX2019005565A (sr) |
MY (1) | MY197564A (sr) |
PL (1) | PL3543240T3 (sr) |
PT (1) | PT3543240T (sr) |
RS (1) | RS63572B1 (sr) |
TW (1) | TWI668213B (sr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3066680C (en) * | 2017-05-26 | 2022-04-12 | Dongfang Shi | Urat1 inhibitor for increasing uric acid excretion |
CN111615515B (zh) * | 2018-01-19 | 2023-11-24 | 苏州信诺维医药科技股份有限公司 | 杂环化合物、制备方法及其在医药上的应用 |
CN108623586B (zh) * | 2018-07-16 | 2021-03-16 | 广东工业大学 | 一种咪唑并含氮杂环类化合物的合成方法与应用 |
CN109432079B (zh) * | 2018-09-07 | 2021-06-22 | 江苏康缘药业股份有限公司 | 一种化合物在制备用于痛风的药物中的应用 |
CN111763180B (zh) * | 2019-04-02 | 2023-06-09 | 中国医学科学院药物研究所 | 苯并氮杂环类化合物及其制法和药物用途 |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
CN111533718B (zh) * | 2020-05-12 | 2022-05-17 | 浙江海洲制药有限公司 | 一种制备苯溴马隆的方法 |
CN112250688B (zh) * | 2020-10-15 | 2022-11-04 | 天津科技大学 | 一类7-氮杂苯并呋喃衍生物及其在抗肿瘤药物中的应用 |
CN112877295A (zh) * | 2021-02-26 | 2021-06-01 | 华南理工大学 | 一种urat1抑制剂体外活性筛选的细胞模型及其构建方法与筛选方法 |
WO2023221078A1 (en) * | 2022-05-20 | 2023-11-23 | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. | Solid forms of a compound for treating or preventing hyperuricemia or gout |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117128A (en) * | 1976-08-03 | 1978-09-26 | Smithkline Corporation | Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity |
NZ193926A (en) | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
FR2502622A1 (fr) * | 1981-03-25 | 1982-10-01 | Synthelabo | Derives d'imidazo (1,2-a) pyrimidines, leur preparation et leur application en therapeutique |
US5175184A (en) * | 1982-10-19 | 1992-12-29 | Kotobuki Seiyaku Company Limited | Benzothiophene derivatives and antihyperuricemia thereof |
JPS5973579A (ja) * | 1982-10-19 | 1984-04-25 | Kotobuki Seiyaku Kk | ベンゾフラン又はベンゾチオフェン誘導体,この化合物を有効成分とする尿酸排泄剤及びその製造方法 |
FR2594438B1 (fr) * | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
GB8820231D0 (en) * | 1988-08-25 | 1988-09-28 | Fujisawa Pharmaceutical Co | New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same |
JP2002514636A (ja) * | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン抵抗性または高血糖症の治療に有用なフェニルオキソ−酢酸類 |
US6166069A (en) * | 1998-05-12 | 2000-12-26 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
KR20040030818A (ko) * | 2001-07-20 | 2004-04-09 | 카로 바이오 아베 | 심방 세동의 치료에 있어서의 벤조 퓨란 및 이들의 용도 |
JP2009227599A (ja) * | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
CN102015726B (zh) | 2008-03-31 | 2014-07-23 | C&C新药研究所 | 杂环衍生物 |
US8748435B2 (en) * | 2011-04-01 | 2014-06-10 | Novartis Ag | Pyrazolo pyrimidine derivatives |
EP2900237A1 (en) * | 2012-09-25 | 2015-08-05 | Novartis AG | Compounds for use in gastric complication |
RU2721844C2 (ru) * | 2014-12-29 | 2020-05-25 | Ниппон Кемифар Ко., Лтд. | Ингибиторы urat1 |
CA2980484C (en) * | 2015-03-24 | 2019-11-26 | Shanghai Yingli Pharmaceutical Co., Ltd | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof |
CN106065010B (zh) * | 2015-04-23 | 2019-01-01 | 镇江新元素医药科技有限公司 | 用于治疗或预防高尿酸血症或痛风的化合物 |
SG11201802010QA (en) * | 2015-09-10 | 2018-04-27 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | A group of compounds used for the treatment or prevention of hyperuricemia or gout |
CN108727267B (zh) * | 2017-05-26 | 2022-05-13 | 江苏新元素医药科技有限公司 | 一类urat1抑制剂及其应用 |
-
2017
- 2017-11-13 CN CN201711115037.9A patent/CN108084186B/zh active Active
- 2017-11-15 MX MX2019005565A patent/MX2019005565A/es unknown
- 2017-11-15 PL PL17872538.8T patent/PL3543240T3/pl unknown
- 2017-11-15 HU HUE17872538A patent/HUE059778T2/hu unknown
- 2017-11-15 US US16/461,298 patent/US10875865B2/en not_active Ceased
- 2017-11-15 ES ES17872538T patent/ES2923177T3/es active Active
- 2017-11-15 KR KR1020197016720A patent/KR102263441B1/ko active IP Right Grant
- 2017-11-15 MY MYPI2019002774A patent/MY197564A/en unknown
- 2017-11-15 DK DK17872538.8T patent/DK3543240T3/da active
- 2017-11-15 AU AU2017360465A patent/AU2017360465B2/en active Active
- 2017-11-15 PT PT178725388T patent/PT3543240T/pt unknown
- 2017-11-15 US US17/707,795 patent/USRE50083E1/en active Active
- 2017-11-15 RS RS20220866A patent/RS63572B1/sr unknown
- 2017-11-15 EP EP17872538.8A patent/EP3543240B1/en active Active
- 2017-11-15 JP JP2019525953A patent/JP6925054B2/ja active Active
- 2017-11-15 CA CA3043942A patent/CA3043942C/en active Active
- 2017-11-15 HR HRP20221151TT patent/HRP20221151T1/hr unknown
- 2017-11-15 TW TW106139575A patent/TWI668213B/zh active
-
2019
- 2019-05-13 IL IL266587A patent/IL266587B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN108084186B (zh) | 2021-06-25 |
USRE50083E1 (en) | 2024-08-20 |
IL266587A (en) | 2019-07-31 |
EP3543240A1 (en) | 2019-09-25 |
US20200062763A1 (en) | 2020-02-27 |
EP3543240A4 (en) | 2020-05-06 |
MX2019005565A (es) | 2019-10-30 |
AU2017360465B2 (en) | 2021-02-04 |
DK3543240T3 (da) | 2022-10-10 |
HUE059778T2 (hu) | 2022-12-28 |
KR102263441B1 (ko) | 2021-06-09 |
PL3543240T3 (pl) | 2022-10-24 |
CA3043942C (en) | 2021-11-02 |
JP2020503263A (ja) | 2020-01-30 |
HRP20221151T1 (hr) | 2022-11-25 |
CN108084186A (zh) | 2018-05-29 |
TWI668213B (zh) | 2019-08-11 |
CA3043942A1 (en) | 2018-05-24 |
US10875865B2 (en) | 2020-12-29 |
KR20190077083A (ko) | 2019-07-02 |
EP3543240B1 (en) | 2022-07-06 |
IL266587B2 (en) | 2023-06-01 |
PT3543240T (pt) | 2022-08-25 |
AU2017360465A1 (en) | 2019-06-06 |
MY197564A (en) | 2023-06-23 |
ES2923177T3 (es) | 2022-09-26 |
TW201819364A (zh) | 2018-06-01 |
JP6925054B2 (ja) | 2021-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243072A1 (zh) | 布羅莫結構域抑制劑及其用途 | |
HK1258689A1 (zh) | 氨基噻唑化合物及其用途 | |
GB201605126D0 (en) | Inhibitors and their uses | |
IL270330B (en) | Beta-lactamase inhibitors and their uses | |
PT3543240T (pt) | Inibidor de urat1 e utilização deste | |
IL264258B (en) | Diazahetero-bicyclic substituted compounds and their use | |
IL264813B (en) | 2-oxo-imidazopyridines and their use | |
EP3336091A4 (en) | IRAQ4 INHIBITOR AND ITS USE | |
EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
PT3621694T (pt) | Inibidores de lrrc33 e sua utilização | |
HUE063848T2 (hu) | LSD1 gátlók és gyógyászati alkalmazásaik | |
EP3336090A4 (en) | INHIBITOR OF IRAQ4 AND ITS USE | |
IL263949A (en) | Complement inhibitors and their uses | |
IL267238A (en) | The paranase inhibitors and their use | |
HK1250926A1 (zh) | 抑制劑及其應用 | |
IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
HK1255029A1 (zh) | 明膠酶抑制劑及其用途 | |
EP3551632C0 (en) | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | |
IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
IL267243A (en) | The paranase inhibitors and their use | |
IL265617B (en) | 1-phenylpropanone compounds and their use | |
IL247872A0 (en) | stat5 inhibitors and their uses | |
GB201505971D0 (en) | Inhibitors and their uses | |
GB201505975D0 (en) | Inhibitors and their uses |